4.4 Biologics, Biosimilars, and Pharmacogenetics
Key Takeaways
- Biologics are complex, high-molecular-weight proteins produced in living systems; biosimilars are authorized by Health Canada based on a totality-of-evidence framework demonstrating no clinically meaningful differences from a reference biologic.
- Monoclonal antibodies are cleared via reticuloendothelial proteolysis and target-mediated disposition; the neonatal Fc receptor (FcRn) protects IgG molecules from lysosomal degradation, extending elimination half-lives to 21-28 days.
- Anti-drug antibodies (ADAs) can neutralize therapeutic epitopes or accelerate immune-complex clearance, leading to loss of response and infusion reactions.
- High-yield pharmacogenetic gene-drug pairs dictate clinical efficacy and toxicity: CYP2C19 loss-of-function (*2, *3) impairs clopidogrel activation; TPMT/NUDT15 deficiency causes life-threatening thiopurine myelosuppression; DPYD deficiency causes fatal fluoropyrimidine toxicity.
- HLA genotyping prevents severe immune-mediated reactions: HLA-B*57:01 screening is mandatory before abacavir; HLA-B*15:02 screening is required in Asian populations before carbamazepine.
Last updated: August 2026
4.4 Biologics, Biosimilars, and Pharmacogenetics
Biotherapeutics and precision pharmacogenetics represent the cutting edge of contemporary clinical pharmacy practice in Canada. Pharmacists must navigate the molecular architecture of biologics, Health Canada biosimilar switching frameworks, monoclonal antibody toxicities, and evidence-based pharmacogenetic guidelines (CPIC and DPWG) to optimize individualized pharmacotherapy.
1. Biologics vs. Small Molecules and Health Canada Biosimilar Framework
+--------------------------------------------------------------------------------------+
| SMALL MOLECULES vs. BIOTHERAPEUTICS COMPARISON |
+--------------------------------------------------------------------------------------+
| Small Molecule Drugs: |
| - Low molecular weight (<1 kDa, e.g., Aspirin: 180 Da, Atorvastatin: 558 Da) |
| - Chemically synthesized; well-defined, identical rigid chemical structure |
| - Non-immunogenic; predictable hepatic CYP450 / renal clearance |
| |
| Biologics / Monoclonal Antibodies: |
| - High molecular weight (~150 kDa for IgG mAbs, e.g., Infliximab: 144,197 Da) |
| - Expressed in living host cells (CHO cells, E. coli); microheterogeneity |
| - Complex 3D tertiary/quaternary folding, post-translational glycosylation |
| - Immunogenic potential (Anti-Drug Antibodies); cleared by RES and FcRn recycling |
+--------------------------------------------------------------------------------------+
Health Canada Biosimilar Authorization Standards
- Definition: A biosimilar is a biologic drug that enters the market subsequent to a version previously authorized in Canada, with demonstrated similarity to a Canadian reference biologic drug.
- Totality of Evidence Approach: Biosimilars are not authorized under standard generic small-molecule bioequivalence criteria ($80.00-125.00%$ AUC confidence intervals). Instead, approval requires extensive structural, physicochemical, functional, non-clinical, and comparative clinical pharmacokinetic, pharmacodynamic, and immunogenicity trials demonstrating no clinically meaningful differences in purity, safety, and efficacy.
- Extrapolation of Indications: Once biosimilarity is established in a sensitive clinical model, Health Canada may grant authorization for other clinical indications held by the reference biologic based on shared pathophysiological mechanisms and receptor targets, without repeating phase III trials in every indication.
- Canadian Naming and Substitution Rules:
- Health Canada authorizes biosimilars with the same International Nonproprietary Name (INN) as the reference product without four-letter suffix modifiers (unlike the US FDA system).
- Interchangeability and Pharmacy Substitution: In Canada, automatic substitution at the pharmacy level without prescriber involvement is regulated provincially. Provincial drug plans (such as BC PharmaCare, Alberta Blue Cross, and Ontario ODB) enforce mandatory biosimilar transition policies requiring patients to switch to an authorized biosimilar for public coverage.
2. Monoclonal Antibody Pharmacokinetics and Targeted Classes
+--------------------------------------------------------------------------------------+
| MONOCLONAL ANTIBODY ELIMINATION AND RECYCLING |
+--------------------------------------------------------------------------------------+
| 1. Fluid-Phase Endocytosis into Endosome (pH ~6.0) |
| 2. Binding of IgG Fc domain to Neonatal Fc Receptor (FcRn) at pH 6.0 |
| 3. Unbound proteins undergo lysosomal proteolysis |
| 4. FcRn-IgG complex trafficked to cell surface; dissociation at pH 7.4 |
| --> Recycles IgG back into systemic circulation, extending t1/2 to 21-28 days |
+--------------------------------------------------------------------------------------+
Therapeutic Monoclonal Antibody Classes and High-Yield Toxicities
| Monoclonal Antibody / Class | Primary Molecular Target | Clinical Indications | Mechanism of Action & Clinical Pearls | Key Adverse Drug Reactions & Safety Warnings |
|---|---|---|---|---|
| Anti-TNF Agents (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept) | Soluble and transmembrane Tumor Necrosis Factor-alpha (TNF-$\alpha$) | Rheumatoid arthritis, Crohn's, Ulcerative Colitis, Plaque Psoriasis | Blocks pro-inflammatory cytokine cascade. Certolizumab pegol lacks an Fc region and does not cross the placenta. | Reactivation of latent tuberculosis (mandatory baseline IGRA/TST), invasive fungal infections, Hepatitis B reactivation, demyelinating disease, worsening CHF (NYHA III/IV contraindicated). Avoid live vaccines. |
| Anti-HER2 (Trastuzumab, Pertuzumab) | Human Epidermal Growth Factor Receptor 2 (HER2/neu, ErbB2) | HER2-positive Breast and Gastric Cancers | Blocks HER2 homodimerization and downstream PI3K/Akt survival signaling | Type II Cardiotoxicity (asymptomatic LVEF decline; non-dose-dependent, reversible unlike anthracyclines). Mandatory baseline and serial ECHO/MUGA. |
| Anti-EGFR (Cetuximab, Panitumumab) | Epidermal Growth Factor Receptor (EGFR / ErbB1) | Metastatic Colorectal Cancer, Head and Neck Cancer | Inhibits EGFR extracellular domain; requires KRAS and NRAS wild-type status (ineffective if mutated) | Acneiform papulopustular rash (severity correlates positively with antitumor response), severe hypomagnesemia (renal TRPM6 channel block). |
| Anti-VEGF (Bevacizumab) | Vascular Endothelial Growth Factor-A (VEGF-A) | Colorectal, Non-Small Cell Lung, Ovarian, Renal Cancers | Neutralizes circulating VEGF-A, inhibiting tumor neoangiogenesis | Severe hypertension, proteinuria/nephrotic syndrome, arterial thromboembolism, GI perforation, impaired wound healing (hold $\ge 4-6\text{ weeks}$ perioperatively). |
| Immune Checkpoint Inhibitors (Pembrolizumab, Nivolumab, Ipilimumab) | PD-1 (Pembrolizumab), PD-L1 (Atezolizumab), CTLA-4 (Ipilimumab) | Melanoma, NSCLC, Renal, Urothelial, MSI-H Cancers | Disinhibits cytotoxic T-lymphocytes, enabling immune-mediated antitumor destruction | Immune-Related Adverse Events (irAEs): Autoimmune colitis, pneumonitis, hepatitis, hypophysitis, thyroiditis. Treated with high-dose corticosteroids (prednisone $1-2\text{ mg/kg/day}$). |
3. Pharmacogenetics: CYP450 Polymorphisms (CPIC Guidelines)
Pharmacogenetics examines how inherited genetic variants alter drug metabolism and receptor responsiveness.
+--------------------------------------------------------------------------------------+
| PHARMACOGENETIC PHENOTYPE CLASSIFICATION (CPIC) |
+--------------------------------------------------------------------------------------+
| 1. Poor Metabolizer (PM) : Complete loss of enzyme activity (two loss alleles)|
| 2. Intermediate Metabolizer (IM): Reduced enzyme activity (one loss allele) |
| 3. Normal Metabolizer (NM) : Fully functional enzyme activity (*1/*1) |
| 4. Rapid Metabolizer (RM) : Increased enzyme activity (*1/*17) |
| 5. Ultrarapid Metabolizer (UM) : Markedly elevated activity (gene duplications) |
+--------------------------------------------------------------------------------------+
High-Yield CYP450 Pharmacogenetic Interactions
- CYP2C19 and Clopidogrel:
- Clopidogrel is an inactive prodrug requiring a two-step hepatic bioactivation, with CYP2C19 mediating both steps to generate the active antiplatelet thiol metabolite.
- Loss-of-Function Alleles: $*2$ (splicing defect) and $*3$ (premature stop codon).
- Clinical Impact: CYP2C19 Poor Metabolizers ($*2/*2, *2/*3$) and Intermediate Metabolizers ($*1/*2, *1/*3$) generate insufficient active metabolite, exhibiting high on-treatment platelet reactivity and elevated risks of stent thrombosis and major adverse cardiovascular events (MACE) following percutaneous coronary intervention (PCI).
- CPIC Recommendation: Switch to alternative antiplatelet agents not reliant on CYP2C19 (prasugrel or ticagrelor).
- CYP2D6 and Codeine / Tramadol / Tamoxifen:
- Codeine is bioactivated by CYP2D6 to morphine (200-fold higher $\mu$-receptor affinity). In Ultrarapid Metabolizers (gene duplications), codeine conversion is excessively rapid, causing fatal respiratory depression (Health Canada contraindication in children $<12\text{ years}$ and nursing mothers).
- Tamoxifen is bioactivated by CYP2D6 to its active metabolite endoxifen. CYP2D6 Poor Metabolizers or patients taking potent CYP2D6 inhibitors (fluoxetine, paroxetine) have reduced endoxifen levels and higher breast cancer recurrence rates.
- CYP2C9 / VKORC1 and Warfarin:
- $(S)$-warfarin is $3-5\times$ more potent than $(R)$-warfarin and is cleared by CYP2C9. Variant alleles CYP2C9*2 (Arg144Cys, $30%$ clearance reduction) and CYP2C9*3 (Ile359Leu, $80-90%$ clearance reduction) impair $(S)$-warfarin clearance.
- The VKORC1 -1639G>A promoter variant reduces vitamin K epoxide reductase enzyme expression. Patients carrying the 'A' allele exhibit heightened warfarin sensitivity and require lower initial and maintenance doses to prevent supratherapeutic INR and hemorrhage.
4. Phase II Conjugation, Transport, and HLA Immunogenetics
+--------------------------------------------------------------------------------------+
| NON-CYP PHARMACOGENETIC TARGETS FOR THE PEBC |
+--------------------------------------------------------------------------------------+
| 1. TPMT / NUDT15 : Thiopurines (Azathioprine, 6-MP) ---> Fatal Myelosuppression |
| 2. DPYD : 5-Fluorouracil / Capecitabine ---> Severe Mucositis & Sepsis |
| 3. UGT1A1 : Irinotecan (SN-38 Clearance) ---> Severe Diarrhea/Neutropenia|
| 4. SLCO1B1 (OATP) : Simvastatin / Statins ---> Myopathy & Rhabdomyolysis |
| 5. HLA-B*57:01 : Abacavir (Anti-HIV) ---> Fatal Hypersensitivity |
| 6. HLA-B*15:02 : Carbamazepine ---> SJS / TEN (Asian Ancestry)|
| 7. HLA-B*58:01 : Allopurinol ---> SCAR / SJS / DRESS |
| 8. G6PD : Rasburicase, Primaquine, Dapsone ---> Acute Hemolytic Anemia |
+--------------------------------------------------------------------------------------+
Detailed Gene-Drug Clinical Profiles
| Gene Target | At-Risk Alleles | Substrate Drugs | Pathophysiological Mechanism of Toxicity | CPIC / Health Canada Clinical Action |
|---|---|---|---|---|
| TPMT & NUDT15 | TPMT $*2, *3A, *3C$; NUDT15 $*3$ | Azathioprine, 6-Mercaptopurine | Inactivating variants fail to metabolize thiopurines, shunting drug toward cytotoxic thioguanine nucleotides (6-TGN) $\to$ catastrophic bone marrow suppression / pancytopenia | Pre-treatment testing recommended. In Poor Metabolizers, reduce dose by $80-90%$ or select alternative therapy; in Intermediate Metabolizers, reduce dose by $30-50%$. |
| DPYD | $*2A$ (c.1905+1G>A), $*13$, c.2846A>T, HapB3 | 5-Fluorouracil (5-FU), Capecitabine | Dihydropyrimidine dehydrogenase (DPD) clears $>80%$ of 5-FU. DPD deficiency causes massive 5-FU accumulation $\to$ severe mucositis, bloody diarrhea, neutropenic sepsis, neurotoxicity | Pre-treatment DPYD testing. In Intermediate Metabolizers, reduce starting dose by $50%$; in Poor Metabolizers, avoid fluoropyrimidines entirely. |
| SLCO1B1 | $*5$ (c.521T>C) | Simvastatin, Atorvastatin | Encodes OATP1B1 hepatic uptake transporter. The $*5$ variant reduces hepatic entry, causing $3-5\times$ higher systemic statin plasma exposure $\to$ skeletal myopathy and rhabdomyolysis | Avoid high-dose simvastatin ($40-80\text{ mg}$); prescribe alternative statins with lower OATP1B1 dependence (rosuvastatin, pravastatin). |
| HLA-B*57:01 | Major histocompatibility complex class I | Abacavir | Abacavir binds specifically in the antigen-recognition groove of HLA-B*57:01, triggering systemic CD8+ T-cell mediated hypersensitivity reaction (fever, rash, GI and respiratory symptoms) | Mandatory pre-treatment screening. If positive, abacavir is permanently contraindicated; rechallenge after reaction can be fatal. |
| HLA-B*15:02 | MHC Class I allele | Carbamazepine, Oxcarbazepine | Presents drug-peptide antigens to cytotoxic T-cells, triggering Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) | Mandatory screening in patients of Asian descent prior to initiating carbamazepine. If positive, avoid carbamazepine. |
| HLA-B*58:01 | MHC Class I allele | Allopurinol | Triggers Severe Cutaneous Adverse Reactions (SCAR: SJS/TEN, DRESS) | Pre-treatment screening recommended in high-risk populations (Han Chinese, Korean, Thai, African ancestry). |
| G6PD | Hemizygous deficient (X-linked) | Rasburicase, Primaquine, Dapsone, Methylene Blue | G6PD deficiency impairs NADPH production and reduced glutathione regeneration. Oxidative stress from rasburicase ($ ext{H}_2 ext{O}_2$ generation) causes acute hemolytic anemia and methemoglobinemia | Rasburicase is strictly contraindicated in G6PD deficiency; pre-treatment screening required in high-risk ancestral groups. |
Test Your Knowledge
A 38-year-old treatment-naive patient newly diagnosed with HIV infection is being evaluated for antiretroviral therapy. The physician plans to prescribe an abacavir-containing regimen. Which mandatory pharmacogenetic screening must be documented prior to dispensing abacavir?
A
B
C
D
Test Your Knowledge
A 58-year-old patient undergoes percutaneous coronary intervention (PCI) with drug-eluting stent placement following an acute myocardial infarction. Pharmacogenetic testing reveals that the patient is a CYP2C19 poor metabolizer (genotype *2/*2). What is the clinical implication of this genotype if the patient is prescribed clopidogrel?
A
B
C
D
Test Your Knowledge
A 52-year-old patient with metastatic colorectal cancer receives their first cycle of chemotherapy containing 5-fluorouracil (5-FU). Within 5 days, the patient develops grade 4 bloody diarrhea, extensive necrotizing stomatitis, profound pancytopenia, and septic shock. An inherited deficiency in which metabolic enzyme is the primary cause of this life-threatening toxicity?
A
B
C
D
Test Your Knowledge
Which statement accurately describes the regulatory framework and clinical pharmacokinetics of biosimilar monoclonal antibodies authorized by Health Canada?
A
B
C
D